

RÉSUMÉ DIGEST

ACT 43 (SB 84)

2021 Regular Session

Talbot

Requires any health coverage plan renewed, delivered, or issued for delivery, in this state to include coverage for genetic or molecular cancer testing including but not limited to tumor mutation testing, next generation sequencing, hereditary germline mutation testing, pharmacogenomic testing, whole exome, genome sequencing and biomarker testing. Provides that coverage may be subject to annual deductibles, coinsurance, copayment provisions consistent with that established under the health coverage plan and that this coverage may be subject to applicable evidence-based medical necessity criteria under the health plan.

Defines health coverage plan as any hospital, health, or medical expense insurance policy, hospital or medical service contract, employee welfare benefit plan, contract, or other agreement with a health maintenance organization or a preferred provider organization, health and accident insurance policy, or any other insurance contract of this type in the state, including group insurance plans, self-insurance plans, and the office of group benefits programs. Excludes a plan providing coverage for excepted benefits in present law, limited benefit health insurance plans, and short-term policies that have a term of less than 12 months.

Defines a biomarker and biomarker testing.

Applies to health coverage plans renewed, delivered, or issued for delivery in their state on or after January 1, 2022.

Effective January 1, 2022.

(Adds R.S. 22:1028.3)